News

Under development by Cytheris, CYT107 is a critical immune-modulator for immune T-cell recovery and enhancement. Clinical trials including more than 180 patients in Europe, North America, South Africa

The increase in revenues is related to comparative higher-than-normal deliveries of Cetrotide to certain customers, as well as to the comparative strengthening of the euro against the US

Novozymes Biopharma claims the product offers optimal viscosity profiles for convenient application and increased patient comfort and compliance while superior heat stability permits autoclaving without loss of product

Graspa is a new enzyme formulation of L-asparaginase with a range of clinical uses compared to existing forms due to the enzymes entrapment and protection inside the homologous

XGEVA, a RANK Ligand inhibitor approved by the US Food and Drug Administration (FDA), is indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases

The company has posted net loss of $9.77m, compared to $8.25m for the same period previous year. Gross profit was $8.39m, compared to $2.28m for the same period

RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the prostate. The double-blind, 12-week,

The company expects to recruit around 880 patients in 48 hospitals in 9 countries across three continents. The study, named as immunotherapy Multikine anti tumor treatments (IT-MATTERS), is

OHR/AVR118 an immunomodulator which modulates cellular pro-inflammatory chemokine and cykotine synthesis, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). The company said OHR/AVR118 has powerful chemoprotective effects which